GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (OSTO:ACE) » Definitions » EBITDA Margin %

Ascelia Pharma AB (OSTO:ACE) EBITDA Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascelia Pharma AB EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ascelia Pharma AB's EBITDA for the three months ended in Dec. 2024 was kr-21.51 Mil. Ascelia Pharma AB's Revenue for the three months ended in Dec. 2024 was kr0.00 Mil. Therefore, Ascelia Pharma AB's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.


Ascelia Pharma AB EBITDA Margin % Historical Data

The historical data trend for Ascelia Pharma AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB EBITDA Margin % Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial - - - - -

Ascelia Pharma AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ascelia Pharma AB's EBITDA Margin %

For the Biotechnology subindustry, Ascelia Pharma AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascelia Pharma AB's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's EBITDA Margin % falls into.


;
;

Ascelia Pharma AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Ascelia Pharma AB's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-66.182/0
= %

Ascelia Pharma AB's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-21.506/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascelia Pharma AB  (OSTO:ACE) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Ascelia Pharma AB EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Ascelia Pharma AB's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascelia Pharma AB Business Description

Traded in Other Exchanges
Address
Hyllie Boulevard 34, Malmo, SWE, SE-215 32
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo Sweden focused on orphan oncology It develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway The company has two drug candidates Orviglance and Oncoral in clinical development.

Ascelia Pharma AB Headlines

No Headlines